Who are Scribe Therapeutics's investors?

Scribe Therapeutics's investors include Andreessen Horowitz, OrbiMed, Avoro Capital Advisors, Menlo Ventures, RA Capital, Avoro Ventures.

How much funding has Scribe Therapeutics raised?

Scribe Therapeutics has disclosed $100M raised across 1 round.

Where is Scribe Therapeutics headquartered?

Scribe Therapeutics is headquartered in Berkeley, US.

Scribe Therapeutics

NASDAQ: SCTX

Berkeley, US · Founded 2017 · Delaware corporation · 89 employees on LinkedIn · 6 known investors

Find your way into Scribe Therapeutics

150 people in our graph share verified history with the Scribe Therapeutics team — schools, employers, funds. One of them is your warm intro.

Katie Riesterunlockedknows Benjamin Oakes · together at Colby College

×6knows the team · via Colby College

×4knows the team · via The Pingry School

knows the team · via Innovative Genomics Institute

Scribe is a molecular engineering company developing CRISPR-based genetic therapies to treat cardiometabolic disease and other conditions. The company uses advanced engineering of natural CRISPR systems to create targeted genetic medicines.

Biotech Deep Tech Healthtech Medical Devices

Founders & leadership

Scribe Therapeutics was founded in 2017 by Benjamin Oakes, Jennifer A. Doudna, PhD, Benjamin L. Oakes, PhD, David F. Savage, PhD, and Brett Staahl, PhD.

Benjamin Oakes inFounder & CEOBenjamin Oakes is the founder and CEO of Scribe Therapeutics, which develops CRISPR-based genetic therapies for cardiometabolic and other diseases.

Jennifer A. Doudna, PhDCo-founder, Scientific Advisor

Benjamin L. Oakes, PhDCo-founder, President and CEO

David F. Savage, PhDCo-founder, Scientific Advisor

Brett Staahl, PhDCo-founder, VP of External Innovation

Board

Vijay Pande in 𝕏Member Board Of Directors2018–2025General Partner, Andreessen Horowitz at Propagator Ventures

Carl Gordon inBoard directorManaging Partner at OrbiMed

Behzad AghazadehBoard directorManaging Partner and Portfolio Manager at Avoro Capital Advisors

Investors · 6

Andreessen Horowitz✓ verifiedMenlo Park · $500K – $50Mvia Vijay Pande · board

OrbiMed✓ verifiedNew York · $1M – $75M

Avoro Capital AdvisorsNew York

Menlo VenturesSan Francisco · $1M – $20M

RA CapitalBoston

Avoro VenturesreportedNew York

Reported raises · per SEC filings

Form D private placements

$100M disclosed across 1 round · 2021

▶$100MraisedApr 2021 · 19 investors · Other Technology

Rule 506(b)

Officers, directors & promoters on the filing

Benjamin OakesExecutive Officer, Director
Vijay PandeDirector
Carl GordonDirector
Behzad AghazadehDirector

Offering amount: $100M
Amount sold: $100M
First sale: Mar 2021
Incorporated: Corporation, Delaware, 2017
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Valuation · disclosed

Disclosed events

$127.5Mvaluation at IPOJul 2026 · $15.00/share · 424B4

filing ↗

Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.

Competitors · 4

by search overlap

CRISPR31 shared keywordsCRISPR Therapeutics is a biotechnology company developing gene-based medicines using CRISPR/Cas9 gene-editing technology. It is led by a management team, board of directors, and scientific founders from the biotech and pharmaceutical industries.

Scribeamerica28 shared keywordsScribeAmerica provides medical scribe services to physicians and healthcare facilities, deploying professional scribes to assist with electronic medical records documentation and patient care. The company serves over 3,500 healthcare clients across 50 states with a workforce of more than 25,000 employees.

Epicrispr Biotechnologies26 shared keywordsEpic CRISPR develops GEMS (Gene Expression Modulation System), a modular epigenetic editing platform that combines DNA-binding proteins, guide RNAs, and modulator proteins to create genetic medicines. The company serves the biotech/medtech sector with advanced tools for precise gene expression control and disease treatment.

Scribe26 shared keywordsScribe automatically captures and documents work processes, converting institutional knowledge into accessible workflows that teams and AI agents can reference. The platform enables organizations to identify inefficiencies, scale best practices, and integrate workflow data with AI tools for training and automation.

Companies competing with Scribe Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Early-stage Scribe wants to write IPO story even as investors favor derisked portfolios - BioSpacebiospace.com · Jul 2026

Scribe Therapeutics Files Nasdaq IPO With $180Mallsci.com · Jul 2026

SCTX IPO News - Cardiovascular diseases biotech Scribe Therapeutics files for a $75 million IPOrenaissancecapital.com · Jul 2026

Scribe Therapeutics files for IPO in test of public appetite for earlier-stage biotechsendpoints.news · Jul 2026

Sell or Invest in Scribe Stock Pre-IPOnasdaqprivatemarket.com · Nov 2024

Frequently asked questions

What does Scribe Therapeutics do?: Scribe is a molecular engineering company developing CRISPR-based genetic therapies to treat cardiometabolic disease and other conditions. The company uses advanced engineering of natural CRISPR systems to create targeted genetic medicines.
Who founded Scribe Therapeutics?: Scribe Therapeutics was founded by Benjamin Oakes, Jennifer A. Doudna, PhD, Benjamin L. Oakes, PhD, David F. Savage, PhD, Brett Staahl, PhD in 2017.
Who are Scribe Therapeutics's investors?: Scribe Therapeutics's investors include Andreessen Horowitz, OrbiMed, Avoro Capital Advisors, Menlo Ventures, RA Capital, Avoro Ventures.
How much funding has Scribe Therapeutics raised?: Scribe Therapeutics has disclosed $100M raised across 1 round.
Where is Scribe Therapeutics headquartered?: Scribe Therapeutics is headquartered in Berkeley, US.